[HTML][HTML] NK cells and ILCs in tumor immunotherapy

S Sivori, D Pende, L Quatrini, G Pietra… - Molecular aspects of …, 2021 - Elsevier
Cells of the innate immunity play an important role in tumor immunotherapy. Thus, NK cells
can control tumor growth and metastatic spread. Thanks to their strong cytolytic activity …

[HTML][HTML] The γc family of cytokines: basic biology to therapeutic ramifications

WJ Leonard, JX Lin, JJ O'Shea - Immunity, 2019 - cell.com
The common cytokine receptor γ chain, γ c, is a component of the receptors for interleukin-2
(IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21. Mutation of the gene encoding γ c results in X-linked …

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

MM Berrien-Elliott, JA Foltz… - Science translational …, 2022 - science.org
Natural killer (NK) cells are innate lymphoid cells that eliminate cancer cells, produce
cytokines, and are being investigated as a nascent cellular immunotherapy. Impaired NK …

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

EJ Fuchs, SR McCurdy, SR Solomon… - Blood, The Journal …, 2022 - ashpublications.org
Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …

[HTML][HTML] Decrease post-transplant relapse using donor-derived expanded NK-cells

SO Ciurea, P Kongtim, D Soebbing, P Trikha… - Leukemia, 2022 - nature.com
In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21
ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid …

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

SR McCurdy, V Radojcic, HL Tsai… - Blood, The Journal …, 2022 - ashpublications.org
The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

[HTML][HTML] Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with …

A Ruggeri, M Labopin, A Bacigalupo… - Journal of hematology & …, 2018 - Springer
Background Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-
host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from …

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell …

SO Ciurea, MM Al Malki, P Kongtim, EJ Fuchs… - Bone marrow …, 2020 - nature.com
The number of HLA-haploidentical hematopoietic cell transplants continues to increase
worldwide due to recent improvements in outcomes, allowing more patients with …

Impaired T-and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide

B Rambaldi, HT Kim, C Reynolds… - Blood …, 2021 - ashpublications.org
Administration of posttransplant cyclophosphamide (PTCy) has significantly expanded the
number of patients undergoing HLA-haploidentical hematopoietic cell transplantation (haplo …

[HTML][HTML] Adaptive NK cell response to human cytomegalovirus: facts and open issues

M López-Botet, A De Maria, A Muntasell… - Seminars in …, 2023 - Elsevier
Human cytomegalovirus (HCMV) infection exerts broad effects on the immune system.
These include the differentiation and persistent expansion of a mature NK cell subset which …